FasL inhibitor speeds recovery and reduces mortality in severe COVID-19 patients

A new clinical study shows that an inhibitor of Fas ligand (FasL), also called CD95 ligand (CD95L), led to a faster recovery of COVID-19 patients and reduced mortality.

NX-1607 by Nurix Therapeutics for Malignant Pleural Mesothelioma: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

October 28, 2023

GE Healthcare Unveils Solutions to Expand Access to Precision Medicine

What You Should Know: – At the Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, GE Healthcare announced new precision medicine to meet

June 8, 2024

How eating alone shapes meal routines in elderly Swedes

Researchers examine the subjective experience and eating habits of elderly Swedish individuals who primarily eat their meals alone.

August 20, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.